Impact Therapeutics, Inc.

Impact Therapeutics (shanghai), Inc

Other

Ye Edward Tian

Xiaozhu Wang

Sui Xiong Cai

Suixiong Cai

Lijun Liu

Qingbing Xu

Chengyun Gu

Xiuhua Hu

Shengzhi Chen

Yang Zhang

Feng Yin

Lizhen Wu

Haijun Dong

Guoxiang Wang

Yangzhen Jiang

Sishun Kang

Qingli Bao

Zheng Meng

Xiuyan Zhang

Sheng Bi

Lei Chen

Zenghui Yu

Zhiqiang Dong

Hongqiang Fei

Dongmei Wang

Compounds represented by Formula I in which A-A, R-R, L, Z and Q are defined herein. The compounds of Formula I are CHK 1 inhibitors. Therefore, the compounds can be used to treat diseases, disorders and conditions associated with continuous activation of CHK1 or with high internal DNA damage or injury during DNA replication, such as cancers.

3,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof

The disclosure provides novel substituted fused heteroaromatic compounds as represented in Formula I, wherein A-Aand R-Rare defined herein. The compounds of Formula I are kinase inhibitors, especially ATR kinase inhibitors. Therefore, the compounds of the disclosure may be used to treat ATR-mediated diseases, disorders and conditions, such as cancer.

Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof

The disclosure relates to substituted fused heteroaromatic tricyclic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A-A, B-B, D-Dand R-Rare defined herein. Compounds having Formula I are ATM kinase inhibitors. Therefore, compounds of the disclosure may be used to treat clinical conditions caused by DDR functional defects, such as cancer.

Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof

Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): 

1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof

Disclosed are 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R-Rare defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.

8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones

Disclosed are imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R-Rare defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.

Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof

The disclosure relates to substituted fused heteroaromatic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I: 

Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof

Disclosed are novel N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs thereof, represented by the Formula I: wherein C cyclic group, D-D, Q, Q, Rare defined herein. Compounds having Formula (I) are hedgehog pathway inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of hedgehog activity, such as cancer. 

N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof

Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones thereof, represented by the Formula (I) wherein Ar, R-Rare defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity. 

[object Object]

Disclosed are 3-aryl-6-aryl-[1,2,4]triazolo[4,3-a]pyridines thereof, represented by the Formula (I) wherein Ar, Ar, R-Rare defined herein. Compounds having Formula (I) are inhibitors of cell proliferation. Therefore, compounds of the invention may be used to treat clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. 

3-aryl-6-aryl-[1,2,4]triazolo[4,3-&#x3b1;]pyridines as inhibitors of cell proliferation and the use thereof

Disclosed are novel 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs thereof, represented by the Formula 1:  wherein Ar, A, R, R-Rare defined herein. Compounds having Formula I are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity, such as cancer.

Growing community of inventors

Jiangsu, China

Ye Edward Tian